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Background: Here, we report the first patient derived hepatitis C virus (HCV) complete genome from Pakistan as is
not available from this region of the world.
Findings: Comprehensive evolutionary and phylogenetic analyses were conducted. The comparison was made in
order to identify evolutionary and molecular phylogenetic relationships among HCV strains belonging to genotype
1a. The evolutionary divergence analysis for nucleotide and amino acid sequences, conducted by equal input
model, suggested that evolutionary nucleotide and amino acid distances showed that the HCV Pakistani strain was
genetically far from Denmark strain (0.29400 nt, 0.819646 aa) and near to German strain (0.06557 nt, 0.139449 aa),
respectively.
Conclusion: The current study will help to understand phylogenetic relationship of circulating Pakistani isolates.
Keywords: HCV genotype 1a, Complete genome comparison, Evolutionary and PhylogeneticBackground
Hepatitis C virus (HCV) is a major worldwide health con-
cern affecting approximately 200 million persons around
the world and is the most common blood-borne infection .
In 60-85% of HCV cases develop cirrhosis and hepatocellu-
lar carcinoma (HCC) [1]. In Pakistan, approximately 17
million people are infected with HCV and 8-10% individ-
uals are HCV carriers [2]. HCV is a member of viral family
Flaviviridae, genus hepacivirus [3]. The HCV genome con-
sists of 9.6 Kb, linear, uncapped and single strand RNA
(ssRNA). The open reading frame is about 9,024 base pair
which encodes a polyprotein of 3010 amino acids [4]. It has
been estimated that 1012 virions per day are produced in
chronically infected patients. This leads to HCV diversity
estimated at 10-3–10-4 base substitutions per site per year
[5]. HCV is classified into genotypes, subtypes, isolates and
quasispecies [6]. Currently HCV is classified into six main
HCV genotypes i.e. 1, 2, 3, 4, 5 and 6 with a genetic
variation at nucleotide/amino acid level at 30% [7].* Correspondence: idrees.khan96@yahoo.com
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distribution, and reproduction in any mediumThese genotypes vary in their geographical distribution,
transmission route and treatment response [8]. Genotypes
3a, 1a and 1b appears to have worldwide distribution due
to their transmission through use of injectable drugs,
blood transfusion and use of improperly sterilized surgical
and medical equipments [9]. Genotype 3a is a common
genotype in South Asia and Pakistan [10-13] 1b and 1a in
the Japan [14], USA and Europe [15], genotype 4 in Middle
East, North and Central Africa [16,17], genotypes 5 in
South Africa and genotypes 6 in Hong Kong [18]. The
Balochistan province of Pakistan has the highest percentage
of 1a (4.03%) [10]; however, the highest prevalence in the
country has been reported from Lahore city (23.6%) [19].
The present study describes the phylogenetic charac-
terization of complete genome of an HCV isolate belonging
to genotype 1a from Pakistan. In spite of the recent devel-
opments we still lack a vaccine against HCV infection.
The standard treatment for HCV is pegylated interferon
alpha separately or with ribavirin [20]. The combine
therapy can eradicate 50% virus in case of genotype 1a.
Due to mutation, viruses have made the way to dodge
IFN dependent immune response [21]. The triple therapy
(PegIFN-α+ribavirin+ protease inhibitors) has 20-39%
higher rates of sustained virological response rate compareentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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is the special characteristic of the RNA molecule. The
variation is the result of the error prone NS5B polymerase
[22]. Due to this lack of accuracy, a diverse population is
generated, called as "quasispecies", almost with a single
mutation in each cycle of replication [23]. Through highly
dynamic process of replication, it can produce 10 trillion
of viruses in a day. This continuing process of mutation
allows the HCV to escape from the host immune response
leading to persistent infection [9,24-26].
A serum from anti-HCV (anti-HCV positive IMX System
ELISA kit Abbot, Germany) and HCV RNA positive
individual was collected. This study was designed to
amplify, clone and sequence genotype 1a cDNA, Pakistan
isolate. Serum sample was genotyped in Molecular
Diagnostics lab, CEMB, University of The Punjab to
detect HCV genotypes and subtypes in Pakistan [27]. The
protocol involved a multiplex PCR [28]. Genotype 1a
samples were selected for further analysis. To amplify
the entire genome of HCV genotype 1a (Pakistani isolate)
in multiple fragments, specific sense and antisense primers
were designed for different regions of HCV genotype 1a
including 5’ UTR Core, E1, E2, P7-NS2, NS3, NS4a, NS4b,
and NS5a, NS5b and 3’ UTR.
Commercially available GF-1 Viral Nucleic Acid
Extraction kit (Vivantis, Cat#GF-RD-300, Vivantis Tech-
nologies, Subang Jaya, Malaysia) was used for RNA extrac-
tion. HCV RNA was extracted from 200 μl serum as per kit
protocol. Complementary DNA (cDNA) was synthesized
by reverse transcribing the extracted RNA (10 μl) with
reverse transcriptase enzyme Maloney Maurine Leukemia
Virus (M-MLV reverse transcriptase enzyme) (Invitrogen,
Life Technologies, NY, USA). The PCR reaction was car-
ried out in a thermal cycler with Taq DNA polymerase
(Invitrogen, Life Technologies, NY, USA). The amplification
was performed with 4 μl of cDNA by using sense and
antisense primers for each gene with reaction mixture
(10X PCR Buffer 2.0 μl, MgCl2 (25 mM) 2.4 μl, dNTPs
(2 mM) 2.0 μl, Outer sense primer (10 pmol/μl) 2.0 μl,
Outer antisense primer (10 pmol/μl) 2.0 μl, dH2O
(nuclease free) up to 4.6 μl, Taq DNA polymerase (5 U/μl)
0.4 U, RT-PCR product 4.0 μl, total reaction volume 20 μl.
Second-round PCR were performed for each sample, nested
PCR was done by using internal primers IAS and IS within
the first round PCR amplicon. PCR products were analyzed
on a 1.2% agarose gel. For purification of DNA from
agarose gel GF-1 Gel DNA Recovery Kit (Vivantis Cat#
GF-GP-100, Vivantis Technologies, Subang Jaya, Malaysia)
was used following the manufacturer’s protocol. Once
pure DNA products were obtained, these products
were accurately quantified using a spectrophotometer
(NanoDrop™, NanoDrop products, USA). Sequencing of
the PCR amplified fragments was performed by triplicate
using gene specific reverse and forward primers in separatereactions. Sequencing was performed according to the
manufacturer’s instructions (Big Dye Deoxy Terminators;
Applied Biosystems, Weiterstadt, Germany) on automated
sequencer (Applied Biosystems; 3100 DNA Analyzer). The
reaction mixture for single reaction consisted of, Big Dye
2 μl, 5X sequencing buffer, 1.5 μl, forward or reverse gene
specific primer 1 μl (10 pmole), sterile dH2O 3.5 μl, template
DNA 2 μl, total reaction volume 10 μl. Once confirmed by
sequencing analysis, cloning of PCR amplified DNA frag-
ments were performed using TA cloning kit (Invitrogen,
USA Cat # K2020-20, Life Technologies, NY, USA). Clones
were sequenced by triplicate to obtain consensus sequence
for entire genes. The sequencing data was then analyzed for
different clones carrying the various fragments of HCV
Genotype 1a and the corresponding consensus sequence
was generated. The sequence was then submitted to NCBI
GenBank database. Homology studies of the nucleotide
sequences of amplified and sequenced PCR products with
known nucleotide sequences present in NCBI was done
through standard nucleotide–nucleotide Blast (Basic Local
Alignment Search Tool) software available at website http://
www.ncbi.nlm.nih.gov/BLAST.
A detail search of Genebank was carried out to find
the sequences from different countries, specially neigh-
boring countries for analysis, of full length sequence of
Hepatitis C virus, subtype 1a. HCV subtype 1a, were not
available from Iran and India. India has reported (8) full
length sequence of 3a, (1) 3i and subtype of a full-length
sequence is not mentioned in Genebank. For Phylogenetic
analysis, and genetic distance, full length genome sequences
representing eight different HCV subtypes 1a were re-
trieved from GenBank database.
These sequences were reported from HCV 1a infected pa-
tients residing in different countries. Denmark AF271632.1,
United Kingdom EU862841, Japan AB520610.1,
Switzerland AF271632.1, Germany AF271632.1, Germany
(Baden-Wurttemberg) EU862841, USA AF271632.1, USA
(Massachusetts Boston area) EU862841, USA (Tennessee)
EU862841, USA: Massachusetts EU862831.1and USA
(New York) EU862841. Pair wise and multiple alignment
of the nucleotide sequences was performed by using
ClustalW [29].Evolutionary relationships of taxa by
Neighbor-Joining method
Phylogenetic analysis was conducted by using Neighbor-
Joining method [30] at 1000 bootstrap analysis and substi-
tutions method was transitions plus transversions using
MEGA 5 software package. The optimal tree with the sum
of branch length was 0.62167471. The evolutionary dis-
tances were computed using the p-distance method and are
in the units of the number of base differences per site. The
analysis involved 12 nucleotide sequences [31] (Figure 1a).
Figure 1 (a) Evolutionary relationships of taxa by Neighbor-Joining method and (1b) Molecular Phylogenetic analysis by Maximum
Likelihood method.
Table 1 Estimates of evolutionary divergence of various
countries (isolate) from KC283194-Pakistani (isolate)
Country Nucleotide Standard Amino
Acid
Standard
Distance Error Distance Error
AF271632.1-Germany 0.06557 0.00246 0.139449 0.007129
EU862841-USA: New York 0.07837 0.00250 0.177424 0.008494
EU862841-Germany:
Baden-Wurttemberg
0.07915 0.00251 0.183177 0.008543
EU862841-United Kingdom 0.08115 0.00286 0.182283 0.009201
AB520610.1-Japan 0.08182 0.00338 0.189850 0.009066
EU862841-USA:
Massachusetts Boston area
0.08772 0.00278 0.205145 0.008760
AF271632.1-Switzerland 0.08906 0.00291 0.208787 0.009882
EU862841-USA: Tennessee 0.09340 0.00279 0.218402 0.009672
AF271632.1-USA 0.09774 0.00296 0.237952 0.010118
EU862831.1-USA:
Massachusetts
0.10431 0.00314 0.252175 0.009941
AF271632.1-Denmark 0.29400 0.00403 0.819646 0.021566
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The evolutionary history was inferred by using the
Maximum Likelihood method based on the General
Time Reversible model. The tree with the highest log
likelihood was (−42333.9343). Initial tree for the heuristic
search were obtained automatically by applying Neighbor-
Join and BioNJ algorithms to a matrix of pairwise distances
estimated using the Maximum Composite Likelihood
(MCL) approach, and then selecting the topology with
superior log likelihood value. The tree was drawn to
scale, with branch lengths measured in the number of
substitutions per site. The analysis involved 12 nucleotide
sequences. Codon positions included were 1st+2nd+3rd+
Noncoding. Substitutions type (nucleotide), very strong
branch swap filter and single number of thread. There were
a total of 9716 positions in the final dataset [31] (Figure 1b).
The estimates of evolutionary divergence analysis for
nucleotide and amino acid was conducted using the
equal input model [32]. The sequences were translated
by Standard genetic code. All positions containing gaps
and missing data were eliminated.
In this study we report the first full length sequence
of HCV Pak-cemb-1 from Pakistan (KC283194). The
estimated of evolutionary divergence of Pakistani
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and (AF271632.1-Denmark 0.29400, (Table 1). The Paki-
stani isolate has travelled an evolutionary nucleotide dis-
tance of approximately 0.22843 nucleotide distance. The
sequence is phylogenetically similar to a German strain in
comparison to the countries USA, United Kingdom,
Switzerland, Japan and Denmark.
HCV infection is a matter of serious concern in Pakistan.
Approximately 17 million people are infected and in the
past ten years the predominant genotype has been shown
to be 3a (60–55.10%), followed by genotype 1a, with a rate
of 10.25% [33,34]. This shows that this virus is rapidly
spreading in Pakistan. However, its various genotypes have
not been characterized genetically except 3a [35]. The
phylogenetic analysis of the full length HCV genotype 1a
confirms the designation of Pakistani isolate to be 1a. It
was found in the same cluster of full length HCV genotype
1a sequences reported from different continents of the
world. The Pakistani isolate has diverged more rapidly
compared to other similar German strain. This indicates
that divergence of this Genotype 1a Pakistani isolate is
occurring at more rapid evolutionary speed in correlation
to other 1a genotype lineages reported from different
regions of the world.
Current therapy of choice is pegylated interferon alpha
separately or in combination ribavirin, which can eradicate
50% virus in case of genotype 1a [20]. The inclusion of
protease inhibitors to the current therapy increases 20-39%
higher rate of sustained virological response rate [21].
Direct acting antiviral agents (telaprevir and boceprevir)
has been approved by FDA, an are recommended for geno-
type 1a. HCV genotype 1a shows greater hindrance to treat-
ment compare to other genotypes. Due to its nature and
prevalence in Pakistan, the evolutionary analysis will help in
the evaluation and development of new antiviral therapies
and possible vaccine development. Moreover, the associ-
ation of HCV genotype 1a full length nucleotide sequences
with the mutational study, epidemiology, severity of disease
and its response to interferon therapy needs to be evaluated
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